Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Public health policy and health economics

4930 - Review on adherence to breast cancer guidelines in Europe


09 Sep 2017


Public health policy and health economics


Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP;  Breast Cancer


Luciana Neamtiu


Annals of Oncology (2017) 28 (suppl_5): v511-v520. 10.1093/annonc/mdx385


L. Neamtiu1, L. Pylkkanen1, C. Freeman2, Z. Saz Parkinson1, S. Deandrea1, A. Uluturk Tekin1, N. Dimitrova1, D. Lerda1

Author affiliations

  • 1 Health In Society, JRC Joint Research Center -European Commision, 21027 - Ispra/IT
  • 2 Freelancer, Freelancer, Barcelona/ES


Abstract 4930


Morbidity and mortality from breast cancer in Europe, as well as costs associated with the disease, remain high. Patients treated according to existing guidelines have better survival. The European Commission Initiative on Breast Cancer (ECIBC) aims to improve quality of care by developing evidence-based breast cancer guidelines and supporting their implementation via a quality assurance scheme for breast cancer services. The goal of this study is to give an overview on compliance with breast cancer guidelines in Europe.


Studies assessing adherence to guidelines on breast cancer screening, diagnosis, treatment and follow-up were searched via Pubmed. Studies published between 1990 and 2016 were included.


In total, 127 studies (mainly observational, retrospective, prospective, and cross sectional) were analysed. The number of participants varied from 56 to 72 000—with studies based on cancer registry data typically including more than 10 000 patients. Overall, adherence to guidelines was variable. Regarding treatment, (e.g. chemotherapy) adherence ranged from 70% to 96% and was approximately 50% for follow-up. Additional or 'unnecessary' procedures were cited as the main causes of non-compliance to follow-up. On the other hand, adherence with respect to radiotherapy (e.g. compliance with technical guidelines) and some safety-related aspects (e.g. cardiac monitoring during adjuvant trastuzumab therapy and prophylaxis with colony-stimulating factors) was substantially lower. Elderly patients were treated less frequently according to existing guidelines. Professionals with less experience (i.e. < 8 years) complied better with guidelines. Use of computerised decision support systems (CDSS) and implementation of a multidisciplinary breast cancer pathway led to better compliance.


In Europe, adherence to guidelines is variable. Implementation of guidelines can help decrease variability in clinical practice, and improve treatment effectiveness and patient safety. Fortunately, adherence can be monitored through the use of quality assurance schemes (e.g., the ECIBC). Incorporating a CDSS within the clinical workflow could reduce the workload of physicians and thus increase their compliance with guidelines.

Clinical trial identification

Not applicable (review).

Legal entity responsible for the study

European Commission, Directorate General Joint Research Centre European Commission, Directorate General Joint Research Centre.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.